KADCYLA is the first and only targeted treatment option in residual invasive HER2+ eBC, supported by 7 years of OS data

https://global.phesgo-hcp.com/kadcyla-residual-invasive.html?cid=na4847551127&utm_source=medscape&utm_medium=na&utm_campaign=her2_2026&utm_content=tx%3Akadcylanc1%3A2609%3Axx&dclid=CjgKEAjwrbfWBhCKtsPFysPgzWkSJACg-Z-IqsDZKANghFA-OccZm_nf9UsMt-DwfS1lNwIfnCdERvD_BwE&gad_source=7